...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Overexpression of Antiapoptotic MCL-1 Predicts Worse Overall Survival of Patients With Non-small Cell Lung Cancer
【24h】

Overexpression of Antiapoptotic MCL-1 Predicts Worse Overall Survival of Patients With Non-small Cell Lung Cancer

机译：抗曝光MCL-1的过度表达预测非小细胞肺癌患者的总体存活率更差

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: Myeloid cell leukemia-1 (MCL1) is a member of the B-cell lymphoma-2 (Bcl-2) family of proteins, which regulate the intrinsic (mitochondrial) apoptotic cascade. MCL-1 inhibits apoptosis, which may be associated with resistance to cancer therapy. Therefore, in this study, the clinical role of MCL-1 in non-small cell lung cancer (NSCLC) was explored. Patients and Methods: This retrospective study included 80 patients with stage 1-3A NSCLC, who underwent surgery without preoperative treatment between 2010 and 2011. MCL-1 expression and Ki-67 index were determined via immunohistochemical staining. Apoptotic index (AI) was determined via terminal deoxynucleotidyl transferase dUTP nick end labeling. Results: The receiver operating characteristic curve analysis (area under curve=0.6785) revealed that MCL-1 expression in 30.0% of the NSCLC tumor cells was a significant cut-off for predicting prognosis. Tumors were considered MCL-1positive if staining was observed in > 30% of the cells. Thirty-six tumors (45.0%) were MCL-1-positive. However, there were no significant differences between MCL- 1 expression and clinical variables. AI was lower in MCL-1positive (2.2 +/- 3.6%) than in MCL-1-negative (5.2 +/- 7.9%) tumors, although the difference was not significant (p=0.1080). The Ki-67 index was significantly higher in MCL-1-positive than in MCL-1-negative tumors (18.0% vs. 3.0%; p<0.001). Five-year survival rate was significantly worse in patients with MCL-1-positive tumors (68.3%) than in those with MCL-1-negative tumors (93.1%, p=0.0057). Univariate [hazard ratio (HR)=5.041, p=0.0013], and multivariate analyses revealed that MCL-1 expression was a significant prognostic factor (HR=3.983, p=0.0411). Conclusion: MCL-1 expression in NSCLC cells correlated inversely with AI and positively with Ki-67 index. MCL-1 may serve as a potential prognostic biomarker and a novel therapeutic target in NSCLC.
机译：背景/目的：骨髓细胞白血病-1（MCL1）是B细胞淋巴瘤-2（BCL-2）蛋白质家族的成员，其调节内在（线粒体）凋亡级联。 MCL-1抑制细胞凋亡，这可能与抗癌疗法有关。因此，在本研究中，探讨了MCL-1在非小细胞肺癌（NSCLC）中的临床作用。患者和方法：该回顾性研究包括80例患有第1-3A期NSCLC患者，在2010和2011年间没有术前治疗的手术中进行手术。通过免疫组化染色测定MCL-1表达和KI-67指数。通过末端脱氧核苷酸转移酶DUTP碎片末端标记测定凋亡指数（AI）。结果：接收器操作特征曲线分析（曲线下面积= 0.6785）显示，30.0％的NSCLC肿瘤细胞中的MCL-1表达是预测预后的显着切断。如果在> 30％的细胞中观察到染色，则认为肿瘤被认为是MCL-1阳性。三十六个肿瘤（45.0％）是MCL-1阳性。然而，MCL-1表达和临床变量之间没有显着差异。虽然差异不显着MCL-1阳性的Ki-67指数显着高于Mcl-1阴性肿瘤（18.0％vs.3.0％; P <0.001）。 MCL-1阳性肿瘤的患者（68.3％）比在MCL-1阴性肿瘤中的患者（93.1％，p = 0.0057），为5年生存率。单变量[危险比（HR）= 5.041，P = 0.0013]和多变量分析显示MCL-1表达是显着的预后因子（HR = 3.983，P = 0.0411）。结论：NSCLC细胞中的MCL-1表达与AI和阳性与KI-67指数相反。 MCL-1可以用作NSCLC中的潜在预后生物标志物和新的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号